News Quantified

SRPT – sarepta therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]

-34.1%

BEAT

7.0%

BEAT

-23.5%

MISS

-3.6%

BEAT

Form 4 Sarepta Therapeutics, For: Nov 28 Filed by: Rothfuss Cristin

Form 4 Sarepta Therapeutics, For: Nov 17 Filed by: Rodino-Klapac Louise

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: D. E. SHAW & CO, L.P.

Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP

Form 10-Q Sarepta Therapeutics, For: Sep 30

Top News Gainers

3/13 Sarepta Therapeutics Inc (NASDAQ: SRPT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 11.5%

2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%

12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%

8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%

10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%

12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%

9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%

10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%

11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%

6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%

Top News Decliners

8/19 Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application -15.0%

3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%

10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%

5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%

2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%

8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%

1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%

8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%

8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%

8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day